Key Insights

Highlights

Treatment Research

6 treatments under study, led by Eribulin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Unknown2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06875128Phase 2RecruitingPrimary

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

NCT05550090UnknownPrimary

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC

NCT05303038Phase 2UnknownPrimary

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Showing all 3 trials

Research Network

Common Treatments

  • Eribulin1
  • Melphalanhds Followed By Physicians Choice Of Soc Eribulin Vinorelbine Or Capecitabine1
  • Vinorelbine Tartrate1
  • Chemotherapy1
  • Physicians Choice Of Soc Eribulin Vinorelbine Or Capecitabine1

Active Sponsors

  • Fudan University1
  • Zhejiang Cancer Hospital1
  • Delcath Systems Inc.1

Top Investigators

Related Conditions

  • Refractory Metastatic Breast Cancer With Liver Dominant Disease1

Activity Timeline